Drug-related IatrogenesisYGénHIALNCT07312019
Optimization of Medical Time in the Emergency Department: Impact of an AI-Based System on Prescription Entry
A study testing current hospital-standard databases and Posos in people with Drug-related Iatrogenesis and Emergency Department, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
Trial summary
Drug-related iatrogenesis is a major public health issue, accounting for a significant proportion of adverse events and hospitalizations in emergency departments. Optimizing prescription management in this context is critical to improve both patient safety and physician efficiency This study aims to evaluate the… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Drug-related Iatrogenesis, Emergency Department, Artificial Intelligence
- What is being tested?
- current hospital-standard databases and Posos
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 770 participants
- Where
- 1 siteFrance
- Study dates
- Jan 2026to Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 years
- Admission to emergency department at a participating center
- Polymedicated patients with prescriptions including ≥8 medication lines (including those for long-term illnesses)
- Signed informed consent
Who cannot join
- Patient under legal protection/judicial measures (guardianship/custody)
- Lack of signed informed consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
CHU Amiens
Amiens, 80480
Aurélien Mary, Pr, 03.22.08.83.71, mary.aurelien@chu-amiens.fr
Daniel Aiham Ghazali, Pr
About this study
Drug-related iatrogenesis is a major public health issue, accounting for a significant proportion of adverse events and hospitalizations in emergency departments. Optimizing prescription management in this context is critical to improve both patient safety and physician efficiency This study aims to evaluate the impact of the POSOS AI-driven device on the medical time required for prescription management in polymedicated patients admitted to emergency departments. The main objective is to establish whether the use of POSOS can reduce transcription time compared to standard electronic management.
- Conditions
- Drug-related Iatrogenesis, Emergency Department, Artificial Intelligence, Clinical Decision Support, Prescription, Transcription
- Being tested
- current hospital-standard databases, Posos
- Keywords
- Drug-related iatrogenesis, emergency department, artificial intelligence, clinical decision support, randomized trial, medication, reconciliation, prescription, transcription
- Medical subject headings
- Emergencies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
current hospital-standard databasesOther
Prescription management using current hospital-standard databases and tools
PososDevice
Prescription management supported by POSOS device (OCR+AI) for structured data entry and clinical decision support
| Study group | Role | What they receive |
|---|---|---|
| Standard prescription | Active comparator | Standard prescription management Receives: Other: current hospital-standard databases |
| PoSOS | Experimental | POSOS-assisted prescription management Receives: Device: Posos |
What is being measured
The primary outcome is the main question the study is designed to answer.
Medical time required for the transcription of prescriptions
Medical time required for the transcription of prescriptions for at-risk polymedicated patients at emergency admission. This is measured by the duration needed to transcribe prescriptions into the structured electronic health record by physicians, assessed by direct observation with a stopwatch
Measured: Day 1
Secondary outcomes (9)
Number of drug-related problems (DRPs) identified per patient
Measured: day 1
Proportion and type of transcription errors (medication name or dosage)
Measured: day 1
Identification of DRPs by subtype and severity
Measured: day 1
Rate of reconciled medication histories and structured documentation
Measured: day 1
Time delays between triage, anamnesis, and diagnosis
Measured: day 1
Length of emergency department stay and downstream hospitalizations
Measured: day 1
Readmission rates
Measured: at 3 months
Overall survival
Measured: at 6 months
Mapping of DRPs by subtype and severity
Measured: day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Dec 2025
- Study startJan 2026 (estimated)
- Primary completionJan 2027 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Drug-related IatrogenesisStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire, AmiensThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 770 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire, Amiens
- Sponsor type
- University, hospital or other
- Collaborators
- Centre Hospitalier Public du Cotentin, University Hospital, Bordeaux, University Hospital, Strasbourg, France, Clinique de l'Estrée, CHU Aix-en-Provence
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07312019
- Sponsor's protocol ID
- PI2024_843_0120
- Acronym
- YGénHIAL
- Status last verified
- Jan 2026
- First submitted
- 17 Nov 2025
- Last updated
- 8 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optimization of Medical Time in the Emergency Department: Impact of an AI-Based System on Prescription Entry
- ClinicalTrials.gov ID
- NCT07312019
- Acronym / sponsor ID
- YGénHIAL / PI2024_843_0120
- Conditions
- Drug-related Iatrogenesis, Emergency Department, Artificial Intelligence, Clinical Decision Support, Prescription, Transcription
- Keywords
- Drug-related iatrogenesis, emergency department, artificial intelligence, clinical decision support, randomized trial, medication, reconciliation, prescription
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 770 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire, AmiensUniversity, hospital or other
- Collaborators
- Centre Hospitalier Public du Cotentin, University Hospital, Bordeaux, University Hospital, Strasbourg, France, Clinique de l'Estrée, CHU Aix-en-Provence
- Study start
- Jan 2026 (estimated)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 31 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Drug-related iatrogenesis is a major public health issue, accounting for a significant proportion of adverse events and hospitalizations in emergency departments. Optimizing prescription management in this context is critical to improve both patient safety and physician efficiency This study aims to evaluate the impact of the POSOS AI-driven device on the medical time required for prescription management in polymedicated patients admitted to emergency departments. The main objective is to establish whether the use of POSOS can reduce transcription time compared to standard electronic management.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard prescription | Active comparator | Other: current hospital-standard databasesStandard prescription management |
| PoSOS | Experimental | Device: PososPOSOS-assisted prescription management |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age ≥18 years
- Admission to emergency department at a participating center
- Polymedicated patients with prescriptions including ≥8 medication lines (including those for long-term illnesses)
- Signed informed consent
Key exclusion criteria (2 listed)
- Patient under legal protection/judicial measures (guardianship/custody)
- Lack of signed informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| current hospital-standard databasesPrescription management using current hospital-standard databases and tools | Other | Standard prescription |
| PososPrescription management supported by POSOS device (OCR+AI) for structured data entry and clinical decision support | Device | PoSOS |
Primary outcome
Medical time required for the transcription of prescriptions
Time frame: Day 1
Medical time required for the transcription of prescriptions for at-risk polymedicated patients at emergency admission. This is measured by the duration needed to transcribe prescriptions into the structured electronic health record by physicians, assessed by direct observation with a stopwatch
9 secondary outcomes
Number of drug-related problems (DRPs) identified per patient
Time frame: day 1
Proportion and type of transcription errors (medication name or dosage)
Time frame: day 1
Identification of DRPs by subtype and severity
Time frame: day 1
Rate of reconciled medication histories and structured documentation
Time frame: day 1
Time delays between triage, anamnesis, and diagnosis
Time frame: day 1
Length of emergency department stay and downstream hospitalizations
Time frame: day 1
Readmission rates
Time frame: at 3 months
Overall survival
Time frame: at 6 months
Mapping of DRPs by subtype and severity
Time frame: day 1
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Drug-related Iatrogenesis
RecruitingObservational study
Identification of Iatrogenic Drug Events Upon Admission to the Adult Emergency Departments
Iatrogenic Drug Events
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing current hospital-standard databases and Posos in people with Drug-related Iatrogenesis and Emergency Department, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aurélien Mary, Pr (33+322088051, mary.aurélien@chu-amiens.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Medical time required for the transcription of prescriptions (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jan 2026.